June 20, 2022 – Roche recently announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. This new solution allows a patient to privately collect her sample for HPV screening while in a healthcare facility, following the directions of a healthcare worker. The clinically validated vaginal sample is analyzed using the Roche cobas® HPV test on a Roche molecular instrument.
Human papillomavirus (HPV) screening can help identify women who are at risk of developing cervical cancer so that the disease can be detected and treated early, before it can develop. There are many factors that contribute to women not participating in cervical cancer screening programs, including limited access to testing, prior experience, embarrassment, and cultural influences. Roche’s self-sampling solution helps break down these barriers by offering women an alternative to more invasive clinical collection procedures while providing accurate and reliable results that enable physicians to make patient care decisions.
“Elimination of cervical cancer is within reach. Breaking down barriers to HPV screening by allowing women to self-collect their own sample for HPV testing is a critical tool in the fight against cervical cancer,” said Thomas Schinecker, CEO of Roche Diagnostics.
In low- and middle-income countries, cervical cancer in women is often diagnosed at a more advanced stage, when the chances of a cure are slim. By expanding access by removing barriers and enabling screening in additional healthcare settings, Roche underscores its commitment to implementing the World Health Organization’s global strategy to eradicate cervical cancer and reduce all-cause mortality.